

Issue of Share Options / PDMR Shareholdings

Released : Apr 01, 2022

RNS Number : 8615G
Diaceutics PLC
01 April 2022

1 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 871,411 share options over ordinary shares of £0.002 each in the Company ("**Share Options**") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.

Share Options were granted as follows:

<i>Name</i>	<i>Number of Share Options granted</i>	<i>Total no. of ordinary shares under option post grant</i>	<i>% of existing issued share capital</i>	<i>Effective Grant date</i>
Peter Keeling, CEO	79,303	332,845	0.40%	1 April 2022
Nick Roberts, CFO	41,838	41,838	0.05%	1 April 2022
Ryan Keeling, CIO	72,290	316,444	0.38%	1 April 2022
Julie Browne, COO and PDMR	51,938	51,938	0.06%	1 April 2022
Jordan Clark, CCO and PDMR	50,495	50,495	0.06%	1 April 2022
Susanne Munksted, CPO and PDMR	50,953	174,075	0.21%	1 April 2022
Stefan McDonald, CGO and PDMR	48,463	81,722	0.10%	1 April 2022
Other employees (34 persons)	476,131	1,095,823	1.30%	1 April 2022

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, including any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 31 March 2021. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 3,191,161, representing approximately 3.80% of its current issued share capital of 84,063,923.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Via Alma PR

Ben Maddison, Stewart Wallace, Nick Adams

Alma PR

Caroline Forde, Kieran Breheny, Matthew Young

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Peter Keeling				
2 Reason for notification						
a.	Position/Status	CEO, Director				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>79,303</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	79,303
Price(s)	Volume(s)					
Exercise price of 0.2p per share	79,303					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		

a.	Name	Nick Roberts				
2 Reason for notification						
a.	Position/Status	CFO, Director				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>41,838</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	41,838
Price(s)	Volume(s)					
Exercise price of 0.2p per share	41,838					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Ryan Keeling
2 Reason for notification		
a.	Position/Status	CIO, Director
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument	Options over new ordinary shares of 0.2p each

	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>72,290</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	72,290
Price(s)	Volume(s)					
Exercise price of 0.2p per share	72,290					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Julie Browne				
2 Reason for notification						
a.	Position/Status	COO and PDMR				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>51,938</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	51,938
Price(s)	Volume(s)					
Exercise price of 0.2p per share	51,938					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		

1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Jordan Clark				
2 Reason for notification						
a.	Position/Status	CCO and PDMR				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>50,495</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	50,495
Price(s)	Volume(s)					
Exercise price of 0.2p per share	50,495					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted
2 Reason for notification		
a.	Position/Status	CPO and PDMR
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		

a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>50,953</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	50,953
Price(s)	Volume(s)					
Exercise price of 0.2p per share	50,953					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Stefan McDonald				
2 Reason for notification						
a.	Position/Status	CGO and PDMR				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>48,463</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	48,463
Price(s)	Volume(s)					
Exercise price of 0.2p per share	48,463					
e.	Date of the transaction	1 April 2022				
f.	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGZGFFLMRGZZM